Treatment selection for patients with relapsed or refractory follicular lymphoma.

ABSTRACT: Follicular lymphoma (FL) is the second most common lymphoma in the United States and is characterized by a variable clinical course, disease heterogeneity, and a relapse-and-remittance pattern historically accompanied by successive shortening of clinical response with every line of treatment. Factors such as progression of disease within 24 months of initial treatment are associated with poor survival outcomes. Although rituximab-based regimens are preferred for early lines of treatment, no clear standard of care exists for treatment of FL in the third-line setting or later as approved third-line treatments have not been compared in a prospective, randomized clinical trial. Rather, physicians may choose from several therapeutic classes with different safety profiles and dosing regimens, wi

SUBMITTER: Skarbnik AZ 

PROVIDER: S-EPMC10028236 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature